arrow
M

Maria-Luisa Schubert

University Hospital Heidelberg
H指数:27
被引数:2,427

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

CD19 CAR-T治疗前B细胞靶向免疫治疗暴露及大B细胞淋巴瘤患者接受CD19 CAR-T治疗后结局:一项EBMT登记研究

2026-09-010
OAAI
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses

一种独特的CAR-T细胞表型介导了有限剂量下的治疗效果

2026-07-290
OA
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT

高危单药难治性和双药难治性慢性淋巴细胞白血病:异基因造血干细胞移植的可行性与影响

2026-06-150
OAAI
Management of immune effector cell-associated neurotoxicity syndrome following CAR-T cell therapy in clinical practice: A multicentric, retrospective, real-world analysis of treatment approaches and outcomes

临床实践中CAR-T细胞疗法后免疫效应细胞相关神经毒性综合征的管理:一种多中心、回顾性、真实世界分析治疗方法和结局

2025-11-010
PRE
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
LEUKEMIA
IF13.4
2024-11-190
PRE
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
LEUKEMIA
IF13.4
2024-08-270
OAAI
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

第三代CD19-directed CAR T细胞治疗成人ALL患者: 一项关键试验的结果

2023-07-2214
OAAI
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
2023-03-1382
OA
Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells
2022-03-019
PRE
Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation

异基因干细胞移植后新型冠状病毒肺炎疫苗接种后体液反应和慢性GVHD加重

2022-02-1811
OAAI
CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells

第三代嵌合抗原受体T细胞和gemtuzumab ozogamicin在完整和CD33-edited急性髓系白血病和造血干细胞和祖细胞中的CD33-directed免疫治疗

2021-11-2328
OA